- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/205 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Campylobacter (G)
Détention brevets de la classe C07K 14/205
Brevets de cette classe: 85
Historique des publications depuis 10 ans
|
6
|
9
|
9
|
6
|
10
|
6
|
5
|
4
|
4
|
3
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Glaxosmithkline Biologicals S.A. | 1650 |
4 |
| The Arizona Board of Regents on Behalf of the University of Arizona | 2179 |
4 |
| Fuso Pharmaceutical Industries, Ltd. | 123 |
4 |
| Biotome Pty Ltd. | 8 |
4 |
| University of Florida Research Foundation, Inc. | 4048 |
3 |
| Board of Trustees of the University of Arkansas | 817 |
3 |
| Sanofi-Aventis U.S. LLC | 51 |
3 |
| Sigma-Aldrich Co., LLC | 251 |
3 |
| Vib VZW | 883 |
3 |
| Vrije Universiteit Brussel | 505 |
3 |
| Eidgenossische Technische Hochschule Zurich | 98 |
2 |
| Industry-Academic Cooperation Foundation, Chosun University | 303 |
2 |
| The Kitasato Institute | 151 |
2 |
| Osaka Prefecture University Public Corporation | 240 |
2 |
| Phylogica Limited | 12 |
2 |
| Porvair Sciences Limited | 13 |
2 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2869 |
2 |
| Universitat Zurich | 651 |
2 |
| Sanofi | 4089 |
2 |
| Elicera Therapeutics AB | 7 |
2 |
| Autres propriétaires | 31 |